Search Results - "Mutnick, AH"

Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000) by Rennie, Robert P., Jones, Ronald N., Mutnick, Alan H.

“…A total of 1,404 bacterial isolates were recovered from skin and soft tissue infections (SSTIs) from hospitalized patients in 24 sites in the United States…”
Get full text

Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997–2000) by Mutnick, Alan H., Biedenbach, Douglas J., Jones, Ronald N.

“…In the 1990s, the Enterococcus emerged as an important pathogen because of increasing prevalence and acquired resistances to glycopeptides and other agents…”
Get full text

Antimicrobial susceptibility patterns of β-hemolytic and viridans group streptococci: report from the SENTRY Antimicrobial Surveillance Program (1997–2000) by Gordon, Kelley A, Beach, Mondell L, Biedenbach, Douglas J, Jones, Ronald N, Rhomberg, Paul R, Mutnick, Alan H

“…Susceptibility patterns of 15 antimicrobial agents were assessed for 3,400 isolates of β-hemolytic (βhS) and viridans group (VgS) streptococci in the four…”
Get full text

Linezolid Resistance Since 2001: SENTRY Antimicrobial Surveillance Program by Mutnick, Alan H, Enne, Victoria, Jones, Ronald N

“…BACKGROUND: The oxazolidinone class of antimicrobials has demonstrated remarkable activity against gram-positive cocci. Linezolid has proven to be a first-line…”
Get full text

Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000) by Hoban, Daryl J, Biedenbach, Douglas J, Mutnick, Alan H, Jones, Ronald N

“…Antimicrobial selection for patients diagnosed with pneumonia is a major therapeutic challenge and dilemma to the clinical practitioner. In the community…”
Get full text

Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999–2001) by Mutnick, Alan H., Rhomberg, Paul R., Sader, Helio S., Jones, Ronald N.

“…Background: The MYSTIC Programme is a global, longitudinal antimicrobial surveillance network of hospitals that frequently utilize carbapenems. One aspect of…”
Get full text

In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci by Jones, Ronald N., Deshpande, Lalitagauri M., Mutnick, Alan H., Biedenbach, Douglas J.

“…Community-acquired and nosocomial infections caused by multidrug-resistant Gram-positive pathogens continue to increase in prevalence and have become a serious…”
Get full text

PCASE6 HOW SHOULD NEWTECHNOLOGIES AND NEW DEVICES BE ASSESSED IN A HOSPITAL SYSTEM? by Mutnick, AH, Wong, PK, Matuszewski, K

Get full text

Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998–2000 by Mutnick, Alan H., Biedenbach, Douglas J., Turnidge, John D., Jones, Ronald N.

“…Resistance (R) among Gram-positive cocci has escalated in the last two decades to levels necessitating the development and use in the newer drug classes,…”
Get full text

CASE 6 THE USE OF AN EVIDENCE-BASED PRACTICE STRATEGY TO IMPROVE QUALITY INTHEACUTE CARE SETTING by Mutnick, AH, Wong, PK, Hanseman, DJ

Get full text

ASHP Guidelines on the pharmacist's role in immunization

Get full text

CANCER Resistance Surveillance Program: Initial Results from Hematology–Oncology Centers in North America by Mutnick, Alan H, Kirby, Jeffrey T, Jones, Ronald N

“…OBJECTIVE The CANCER (Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance) surveillance program was initiated to collect culture data…”
Get full text

Contemporary evaluation of the in vitro activity and spectrum of cefdinir compared with other orally administered antimicrobials tested against common respiratory tract pathogens (2000-2002) by Sader, Helio S, Fritsche, Thomas R, Mutnick, Alan H, Jones, Ronald N

“…Cefdinir is an oral cephalosporin approved by the Food and Drug Administration in 1997 for the treatment of acute exacerbation of chronic bronchitis,…”
Get full text

Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000) by Kirby, Jeffrey T, Mutnick, Alan H, Jones, Ronald N, Biedenbach, Douglas J, Pfaller, Michael A

“…The antimicrobial activity of garenoxacin, a des-(6)F quinolone (formally BMS284756 and T-3811), was evaluated against 2,537 skin and soft tissue infection…”
Get full text

A Cost-Effectiveness Analysis of Stress Ulcer Prophylaxis by Schupp, Kelly N, Schrand, Linda M, Mutnick, Alan H

“…OBJECTIVE: To evaluate the efficacy, safety, and cost of using cimetidine, famotidine, and lansoprazole for stress ulcer prophylaxis (SUP) at our institution…”
Get full text

Impact of Modified Nonmeningeal Streptococcus pneumoniae Interpretive Criteria (NCCLS M100-S12) on the Susceptibility Patterns of Five Parenteral Cephalosporins: Report from the SENTRY Antimicrobial Surveillance Program (1997 to 2001) by JONES, Ronald N, MUTNICK, Alan H, VARNAM, David J

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Cost savings and avoidance from clinical interventions by Mutnick, AH, Sterba, KJ, Peroutka, JA, Sloan, NE, Beltz, EA, Sorenson, MK

“…A method that lets a pharmacy department collect data on cost savings and avoidance achieved through pharmacist interventions is described. The pharmacist…”
Get full text

A cost-benefit analysis of RSV prophylaxis in high-risk infants by Schrand, LM, Elliott, JM, Ross, MB, Bell, EF, Mutnick, AH

“…OBJECTIVE: To determine the cost and benefit of using RSV-IG and palivizumab as prophylactic therapy against respiratory syncytial virus (RSV)–associated…”
Get full text

Emerging Antimicrobial Resistances Among Proteus mirabilis in Europe: Report from the MYSTIC Program (1997-2001) by Mutnick, A.H., Turner, P.J., Jones, R.N.

“…Resistance patterns that are currently problematic in Europe can vary greatly within the same species over time, among various patient populations and among…”
Get full text

Antimicrobial activity of LB10827, a new orally administered cephalosporin, tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae by Deshpande, L.M., Beach, M.L., Mutnick, A. H, Jones, R.N.

“…A new orally administered cephalosporin, LB10827, was compared to 16 other antimicrobial agents tested against Streptococcus pneumoniae (520 strains),…”
Get full text